Focus on : Contemporary Methods in Biostatistics ( II ) An Introduction to Competing Risks Analysis

The need to develop treatments and/or programs specific to a disease requires the analysis of outcomes to be specific to that disease. Such endpoints as heart failure, death due to a specific disease, or control of local disease in cancer may become impossible to observe due to a prior occurrence of a different type of event (such as death from another cause). The event which hinders or changes the possibility of observing the event of interest is called a competing risk. The usual techniques for time-to-event analysis applied in the presence of competing risks give biased or uninterpretable results. The estimation of the probability of the event therefore needs to be calculated using specific techniques such as the cumulative incidence function introduced by Kalbfleisch and Prentice. The model introduced by Fine and Gray can be applied to test a covariate when competing risks are present. Using specific techniques for the analysis of competing risks will ensure that the results are unbiased and can be correctly interpreted. Full English text available from: www.revespcardiol.org.

[1]  J. Nordrehaug,et al.  Competing risk analysis of events 10 years after revascularization , 2010, Scandinavian cardiovascular journal : SCJ.

[2]  W. R. Buckland Theory of Competing Risks , 1978 .

[3]  L. Mell,et al.  Pitfalls of using composite primary end points in the presence of competing risks. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Satagopan,et al.  A note on competing risks in survival data analysis , 2004, British Journal of Cancer.

[5]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[6]  E. Núñez,et al.  Insuficiencia cardiaca aguda post-alta hospitalaria tras un síndrome coronario agudo sin elevación del segmento-ST y riesgo de muerte e infarto agudo de miocardio subsiguiente , 2010 .

[7]  M. Pintilie,et al.  The analysis of case cohort design in the presence of competing risks with application to estimate the risk of delayed cardiac toxicity among Hodgkin Lymphoma survivors , 2010, Statistics in medicine.

[8]  Melania Pintilie,et al.  Competing Risks: A Practical Perspective , 2006 .

[9]  M S Pepe,et al.  Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? , 1993, Statistics in medicine.

[10]  J. Seward,et al.  Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. , 2007, European heart journal.

[11]  William A Ghali,et al.  Kaplan-Meier methods yielded misleading results in competing risk scenarios. , 2006, Journal of clinical epidemiology.

[12]  S. Solomon,et al.  Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. , 2009, European heart journal.

[13]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[14]  B. Freidlin,et al.  Testing treatment effects in the presence of competing risks , 2005, Statistics in medicine.

[15]  H Putter,et al.  Long‐term survival with non‐proportional hazards: results from the Dutch Gastric Cancer Trial , 2005, Statistics in medicine.

[16]  R. Doughty,et al.  Prognostic role of echocardiography and brain natriuretic peptide in symptomatic breathless patients in the community. , 2008, European heart journal.

[17]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[18]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[19]  R. Gray A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[20]  R. Gelber,et al.  Improved methodology for analyzing local and distant recurrence. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Jason Fine,et al.  Competing Risks Regression for Stratified Data , 2011, Biometrics.

[22]  Ravi Varadhan,et al.  Evaluating Health Outcomes in the Presence of Competing Risks: A Review of Statistical Methods and Clinical Applications , 2010, Medical care.

[23]  D.,et al.  Regression Models and Life-Tables , 2022 .

[24]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.